30 completed, 3 not yet recruiting, 3 terminated. 12 Phase 1, 12 Phase 2, 9 Phase 3, 1 Not applicable, 1 Phase 4.
By phase and status
Follow GSK1278863: new trials by email Literature Review of GSK1278863 trials Research Report on GSK1278863
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis Epoetin Alfa (drug), Daprodustat - Chronic Kidney Disease (Stages 3b-5), Anemia Associated With Chronic Kidney Disease Not applicable Not yet recruiting Services Hospital, Lahore 60 2026-09-01 2026-08-10 REDCURE Registry for Chronic Kidney Disease (CKD) Anemia Daprodustat - CKD Anemia Not yet recruiting Nabiqasim Industries (Pvt) Ltd 384 2026-01-30 2026-01-20 A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) Daprodustat, Darbepoetin alfa - Anaemia Phase 3 Not yet recruiting Qilu Pharmaceutical Co., Ltd. 100 2025-12-31 2025-12-23 Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P) Daprodustat - Anaemia Phase 3 Completed GlaxoSmithKline 4 2023-09-06 2025-11-10 A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease Daprodustat - Anemia, Renal Insufficiency, Chronic Phase 4 Completed USRC Kidney Research 161 2023-07-01 2024-05-24 Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants Daprodustat - Anaemia Phase 1 Completed GlaxoSmithKline 259 2020-12-18 2025-04-10 Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe) Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe) - Anaemia Phase 2 Completed GlaxoSmithKline 15 2019-07-30 2024-03-27 Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF) Daprodustat, Darbepoetin alfa, Acetylcholine - Anaemia Phase 2 Terminated GlaxoSmithKline 6 2019-01-10 2024-03-27 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials - Anaemia Phase 3 Completed GlaxoSmithKline 407 2018-09-05 2021-07-12 Daprodustat Bioequivalence and Food Effect Study Daprodustat 2 mg tablet, Daprodustat 4 mg tablet - Anaemia Phase 1 Completed GlaxoSmithKline 64 2018-04-24 2020-07-08 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ) Daprodustat (GSK1278863), Placebo, Iron therapy - Anaemia Phase 3 Completed GlaxoSmithKline 614 2018-03-05 2024-04-02 Absorption and Elimination of Radiolabeled Daprodustat [14C]-GSK1278863 solution for IV infusion, [14C]-GSK1278863 oral solution, Daprodustat 6 mg oral tablet - Anaemia Phase 1 Completed GlaxoSmithKline 6 2017-10-10 2019-12-03 Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) Daprodustat, Epoetin alfa - Anaemia Phase 2 Completed GlaxoSmithKline 105 2017-07-27 2021-06-03 Daprodustat Hepatic Impairment Study Daprodustat (GSK1278863) - Anaemia Phase 1 Completed GlaxoSmithKline 37 2017-07-24 2019-09-04 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) Daprodustat, Darbepoetin alfa, Iron therapy - Anaemia Phase 3 Completed GlaxoSmithKline 312 2017-05-11 2021-10-20 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Daprodustat, rhEPO, Placebo - Anaemia, Aspergillosis, Allergic Bronchopulmonary Phase 3 Completed GlaxoSmithKline 2964 2016-09-28 2021-12-03 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Daprodustat, Darbepoetin alfa, Placebo - Anaemia Phase 3 Completed GlaxoSmithKline 3872 2016-09-27 2024-04-02 Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents GSK1278863, Iron - Anaemia Phase 3 Completed GlaxoSmithKline 28 2016-08-08 2019-12-03 Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia 1 to 4 mg tablets of GSK1278863, 6 mg GSK1278863 tablet, Epoetin beta pegol - Anaemia Phase 3 Completed GlaxoSmithKline 355 2016-06-06 2021-05-18 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent GSK1278863, GSK1278863 matching Placebo - Anaemia Phase 2 Completed GlaxoSmithKline 103 2016-02-17 2020-02-25
Showing 20 of 36. Sign in to see all of them.
Conditions studied Anemia (31) · Renal Insufficiency, Chronic (17) · Aspergillosis, Allergic Bronchopulmonary (1) · Diabetic Foot (1) · Ischemia (1) · Kidney Failure, Chronic (1) · Myalgia (1) · Peripheral Vascular Diseases (1) · Renal Insufficiency (1) · Tendon Injuries (1)
Sponsors GlaxoSmithKline (32) · Nabiqasim Industries (Pvt) Ltd (1) · Qilu Pharmaceutical Co., Ltd. (1) · Services Hospital, Lahore (1) · USRC Kidney Research (1)
Countries United States (25) · Canada (11) · United Kingdom (9) · Germany (8) · Russia (8) · South Korea (8) · Spain (8) · Australia (7) · Japan (7) · Poland (7) · France (6) · Argentina (5) · Denmark (5) · Italy (5) · Sweden (5)
Top investigators Geoffrey Block, MD (1)
Results publications PMID 36005278 , PMID 26494831 , PMID 36565721 , PMID 38383961 , PMID 25135232 , PMID 25377872 , PMID 33561857 , PMID 33744933 , PMID 34739194 , PMID 35355447 , PMID 35377393 , PMID 35918106 , PMID 36739866
NIH funding 2017 (4), 2016 (3), 2014 (1), 2015 (1)